More on TCRX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $0.32 |
|
|||
| Open | $0.32 | ||||
| 52 Wk High | $26.80 | ||||
| 52 Wk Low | $23.00 | ||||
| Day High | $0.33 | ||||
| Day Low | $0.31 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 833,159 | ||||
- Form 8-K TScan Therapeutics, Inc. For: Sep 08
- H.C. Wainwright Downgrades Tscan Therapeutics Inc (TCRX) to Neutral
- Needham Downgrades Tscan Therapeutics Inc (TCRX) to Hold
- Wedbush Downgrades Tscan Therapeutics Inc (TCRX) to Neutral
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
- TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
- Form 8-K TScan Therapeutics, Inc. For: Aug 12
- Form SCHEDULE 13G/A TScan Therapeutics, Inc. Filed by: Lynx1 Capital Management LP
- Form SCHEDULE 13G/A TScan Therapeutics, Inc. Filed by: BIOTECHNOLOGY VALUE FUND L P
- H.C. Wainwright Reiterates Buy Rating on Tscan Therapeutics Inc (TCRX)
Entities mentioned with TCRX
- FDA | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- Morgan Stanley | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- S3 | View Related Stories »
- Show More...
